KURA

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 26.88 USD with a low forecast of 11.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kura Oncology Inc revenue for the last quarter amounts to 20.75M USD, decreased % YoY.

Kura Oncology Inc. EPS for the last quarter amounts to -0.85 USD, increased 34.92 % YoY.

Kura Oncology Inc (KURA) has 192 emplpoyees as of December 15 2025.

Today KURA has the market capitalization of 889.32M USD.